Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AbbVie Exercises Right to Acquire TeneoOne and TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

americanpharmaceuticalreviewJune 25, 2021

Tag: AbbVie , TeneoOne , Teneobio , TNB-383B

PharmaSources Customer Service